ATE223711T1 - Tts enthaltend ein antioxidans - Google Patents

Tts enthaltend ein antioxidans

Info

Publication number
ATE223711T1
ATE223711T1 AT99902525T AT99902525T ATE223711T1 AT E223711 T1 ATE223711 T1 AT E223711T1 AT 99902525 T AT99902525 T AT 99902525T AT 99902525 T AT99902525 T AT 99902525T AT E223711 T1 ATE223711 T1 AT E223711T1
Authority
AT
Austria
Prior art keywords
antioxidant
ethyl
tts
contain
tts contain
Prior art date
Application number
AT99902525T
Other languages
English (en)
Inventor
Bodo Asmussen
Michael Horstmann
Kai Koepke
Harry Tiemessen
Original Assignee
Novartis Erfind Verwalt Gmbh
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10825116&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE223711(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Erfind Verwalt Gmbh, Lohmann Therapie Syst Lts filed Critical Novartis Erfind Verwalt Gmbh
Application granted granted Critical
Publication of ATE223711T1 publication Critical patent/ATE223711T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dental Preparations (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99902525T 1998-01-12 1999-01-08 Tts enthaltend ein antioxidans ATE223711T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800526.7A GB9800526D0 (en) 1998-01-12 1998-01-12 Organic compounds
PCT/EP1999/000078 WO1999034782A1 (en) 1998-01-12 1999-01-08 Tts containing an antioxidant

Publications (1)

Publication Number Publication Date
ATE223711T1 true ATE223711T1 (de) 2002-09-15

Family

ID=10825116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902525T ATE223711T1 (de) 1998-01-12 1999-01-08 Tts enthaltend ein antioxidans

Country Status (26)

Country Link
US (1) US6335031B1 (de)
EP (1) EP1047409B1 (de)
KR (1) KR100569051B1 (de)
CN (1) CN1129427C (de)
AT (1) ATE223711T1 (de)
AU (1) AU745661B2 (de)
BR (1) BR9906920A (de)
CA (1) CA2315784C (de)
CZ (1) CZ300598B6 (de)
DE (1) DE69902875T2 (de)
DK (1) DK1047409T3 (de)
ES (1) ES2184408T3 (de)
GB (1) GB9800526D0 (de)
HK (1) HK1034036A1 (de)
HU (1) HU227159B1 (de)
ID (1) ID27503A (de)
IL (1) IL137100A (de)
MX (1) MXPA00006438A (de)
NO (1) NO328390B1 (de)
NZ (1) NZ505650A (de)
PL (1) PL201328B1 (de)
PT (1) PT1047409E (de)
RU (1) RU2219926C2 (de)
SK (1) SK284622B6 (de)
TR (2) TR200001688T2 (de)
WO (1) WO1999034782A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69923200T2 (de) * 1998-10-01 2005-12-22 Novartis Ag Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
RU2266735C2 (ru) * 1999-11-29 2005-12-27 Лтс Ломанн Терапи-Системе Аг Трансдермальные терапевтические системы с повышенной стабильностью и способ их получения
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
ITMI20020798A1 (it) * 2002-04-15 2003-10-15 F T Holding S A Cerotti transdermici a matrice adesiva siliconica stabilizzati con copolimeri metacrilici
FR2881653A1 (fr) * 2005-02-04 2006-08-11 Frederic Khodja Dispositif permettant l'administration en continu d'une dose physiologique controlee d'au moins un mineral ou une vitamine
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
PE20110591A1 (es) 2008-07-28 2011-09-15 Takeda Pharmaceutical Composicion farmaceutica estabilizada a base de un compuesto no peptidico
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
JP6083734B2 (ja) 2009-12-22 2017-02-22 リュイェ ファーマ アーゲーＬｕｙｅ Ｐｈａｒｍａ ＡＧ リバスチグミンまたはその誘導体を投与するための経皮治療システム
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DE102010026903A1 (de) 2010-07-12 2012-01-12 Amw Gmbh Transdermales therapeutisches System mit Avocadoöl oder Palmöl als Hilfsstoff
SG10201505658RA (en) 2010-07-21 2015-09-29 3M Innovative Properties Co Transdermal adhesive compositions, devices, and methods
ES2545094T3 (es) * 2010-12-14 2015-09-08 Acino Ag Sistema terapéutico transdérmico para la administración de un principio activo
KR101788802B1 (ko) * 2010-12-24 2017-10-20 주식회사 삼양바이오팜 리바스티그민을 함유하는 경피흡수제제
KR20120126898A (ko) * 2011-05-13 2012-11-21 에스케이케미칼주식회사 리바스티그민 또는 이의 염을 함유하는 경피 투여 조성물
KR20120130073A (ko) * 2011-05-20 2012-11-28 에스케이케미칼주식회사 리바스티그민 함유 패취
WO2012161489A2 (ko) 2011-05-20 2012-11-29 에스케이케미칼 주식회사 리바스티그민 함유 패취
EP2594261A1 (de) 2011-11-18 2013-05-22 Labtec GmbH Zusammensetzung zur transdermalen Verabreichung von Rivastigmin
DE102012000369A1 (de) 2012-01-11 2013-07-11 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System mit Cholinesterase-Hemmer
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
JP6153135B2 (ja) 2012-06-12 2017-06-28 株式会社 ケイ・エム トランスダーム 貼付剤
EP2893927A4 (de) * 2012-09-03 2016-03-09 Nipro Patch Co Ltd Hautpflaster
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
WO2014051128A1 (ja) 2012-09-28 2014-04-03 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
CN106413695B (zh) * 2014-04-08 2019-12-10 帝国制药美国公司 利伐斯的明透皮组合物及其使用方法
JPWO2015174502A1 (ja) 2014-05-15 2017-05-25 ニチバン株式会社 リバスチグミンを含有する貼付剤のための包装体
KR20200025883A (ko) 2018-08-31 2020-03-10 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취
KR20200025888A (ko) 2018-08-31 2020-03-10 에스케이케미칼 주식회사 장기 투여용 리바스티그민 패취

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
AU5716898A (en) * 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
EP0952826B1 (de) * 1997-01-17 2001-11-14 Takeda Chemical Industries, Ltd. Idebenon enthaltendes kombinationspräparat zur alzheimer behandlung

Also Published As

Publication number Publication date
SK10532000A3 (sk) 2000-11-07
AU2278599A (en) 1999-07-26
ID27503A (id) 2001-04-12
PT1047409E (pt) 2002-12-31
KR20010033072A (ko) 2001-04-25
HUP0004300A3 (en) 2003-05-28
CA2315784C (en) 2006-06-27
MXPA00006438A (es) 2003-07-21
ES2184408T3 (es) 2003-04-01
HUP0004300A2 (hu) 2001-05-28
CA2315784A1 (en) 1999-07-15
DK1047409T3 (da) 2002-12-30
AU745661B2 (en) 2002-03-28
DE69902875D1 (de) 2002-10-17
WO1999034782A1 (en) 1999-07-15
NO20003472L (no) 2000-08-07
CN1288375A (zh) 2001-03-21
RU2219926C2 (ru) 2003-12-27
HK1034036A1 (en) 2001-10-12
EP1047409B1 (de) 2002-09-11
SK284622B6 (sk) 2005-08-04
US6335031B1 (en) 2002-01-01
CZ300598B6 (cs) 2009-06-24
PL341347A1 (en) 2001-04-09
IL137100A0 (en) 2001-06-14
GB9800526D0 (en) 1998-03-11
DE69902875T2 (de) 2003-05-22
IL137100A (en) 2004-12-15
NO20003472D0 (no) 2000-07-05
HU227159B1 (en) 2010-09-28
PL201328B1 (pl) 2009-03-31
KR100569051B1 (ko) 2006-04-10
TR200101021T2 (tr) 2002-06-21
JP2002500178A (ja) 2002-01-08
EP1047409A1 (de) 2000-11-02
CZ20002557A3 (cs) 2000-10-11
BR9906920A (pt) 2000-10-10
NO328390B1 (no) 2010-02-08
JP3820103B2 (ja) 2006-09-13
NZ505650A (en) 2002-10-25
CN1129427C (zh) 2003-12-03
TR200001688T2 (tr) 2000-11-21

Similar Documents

Publication Publication Date Title
ATE223711T1 (de) Tts enthaltend ein antioxidans
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ATE383849T1 (de) Transdermale pharmazeutische zusammensetzung
AR037081A1 (es) Composicion para el suministro transdermico de fentanilo
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
MA25681A1 (fr) Systeme d'administration de compositions orales de soins comprenant une resine d'organosiloxane utilisant une bandelette de soutien amovible.
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
ES2160163T3 (es) Composiciones farmaceuticas a base de derivados de la clase de los taxanos.
MXPA05010607A (es) Composiciones de distribucion de farmacos de ester de alfa-hidroxiacido y metodos de uso.
HRP20080178T3 (en) Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
EP1300143A4 (de) Pflaster mit 4-biphenylessigsäure
TR200400241T4 (tr) Lasofoksifen'in transdermal olarak verilmesi
GEP20094648B (en) Anti-parasiticidal composition
IT1291895B1 (it) Preparazione farmaceutica fluida a base di nimesulide per uso orale e rinofaringeo
ATE102934T1 (de) Fluorierte flavon-essigsaeure.
TR200301552A1 (tr) Rofekoksib' in yeni oral farmakolojik formülasyonları.
BR0214644A (pt) Uso de derivados de ácido 4-oxobutanóico no tratamento de inflamação

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification